We've had Eyes on the evolving Pharma Pipeline Strategy. This week we highlight how many companies are leaning on external innovation with full acquisition s to targeted asset deals to drive long-term strategy.

We're keeping Eyes On Diabesity. With new approvals, data on the horizon, and M&A to bolster pipelines, it seems like there's something new everyday. Here we cover new MACE indications and the Metsera bidding war. What were you watching?